Network·Hedge Fund
📍 NEW YORK, NY
SEC CRD #802-74394
Aisling Capital | Home Largest provider of biopharmaceutical development and commercial outsourcing services. Learn More About Quintiles Highly selective medicines for genomically defined cancers. Aisling congratulates the management team of Loxo on its recent acquisition by Eli Lilly. Learn More About Loxo Developing late-stage neuroscience compounds targeting migraine and psychiatric disorders. Learn More About Biohaven Novel treatments for people living with narcolepsy and other central nervous system disorders. Learn More About Harmony CoolSculpting®: more science, less fat. Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan. Learn More About ZELTIQ Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy Learn More About Aimmune Aimmune Loxo Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies. Meet Our Team A combined 150+ years of experience in the healthcare industry. Learn More about Team See Our Portfolio $1.8 billion in assets, with a track record of investing and returning capital since 2000. Learn More about Portfolio Latest News BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 May 12, 2026 Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstra
ROBERT WENZEL
CHIEF COMPLIANCE OFFICER; CHIEF FINANCIAL OFFICER
📞 (212) 651-6380
🔒 Sign up for free to view key contact information
Sign up free →This profile has not yet been verified by the firm. Information may be incomplete or outdated. Claim this profile to take control of your listing.
Check Size
$1M–$1M
Location
NEW YORK, NY
Claim this profile to complete your information, set investment criteria, and start receiving curated deal flow from sponsors on DEALITHIC.